Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aethlon Medical, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AEMD
Nasdaq
2834
www.aethlonmedical.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aethlon Medical, Inc.
Q3 2025 Aethlon Medical Inc Earnings Call
- Feb 13th, 2025 6:08 pm
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
- Feb 13th, 2025 1:01 pm
AEMD: Patient Enrollments in Oncology Trial Expected to Accelerate With 3rd Participating Site, Protocol Amendments
- Feb 13th, 2025 12:18 pm
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
- Feb 12th, 2025 9:15 pm
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
- Feb 5th, 2025 1:01 pm
Aethlon Medical treats first subject with Hemopurifier device in Australia
- Jan 30th, 2025 3:00 pm
AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of Hemopurifier
- Jan 30th, 2025 11:00 am
Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial
- Jan 29th, 2025 1:01 pm
Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
- Dec 20th, 2024 1:01 pm
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
- Dec 3rd, 2024 12:00 pm
AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures
- Nov 14th, 2024 2:09 pm
Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally
- Nov 14th, 2024 1:00 pm
Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...
- Nov 14th, 2024 7:14 am
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
- Nov 13th, 2024 9:15 pm
Innovative Medical Technology Advances with First Patient Enrollments
- Nov 12th, 2024 1:00 pm
Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer
- Nov 11th, 2024 4:18 pm
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
- Nov 11th, 2024 1:01 pm
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
- Nov 6th, 2024 1:01 pm
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
- Oct 29th, 2024 11:00 am
OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, Interim CEO & CFO, and Steven LaRosa, MD, Chief Medical Officer, of Aethlon Medical Inc., with Marla Marin, Senior Analyst at Zacks SCR
- Oct 25th, 2024 1:07 pm
Scroll